Table 1.
Analysis of % of ERBB family gene mutations and PIK3CA mutations in 81 different cancer databases reported on the www.cbioportal.org website as of 26 July 2016.8 The table includes data for % of individual ERBB mutations, as well as the % of tumors which have dual ERBB family/PIK3CA mutations.
| Study ID | Study/cancer type | No. cases | % PIK3CA | % EGFR | % ERBB2 | % ERBB3 | % ERBB4 | % ERBB mutation | Co-occurrence | % HER WT/PIK3CA WT | % ERBB/PIK3CA dual mutants | % PIK3CA Mut only | % ERBB family Mut only |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| TCGA | Adrenocortical carcinoma (TCGA, provisional) | 90 | 1.1 | 3.0 | 0.0 | 1.1 | 3.0 | 7.1 | N | 91.8 | 0.0 | 1.1 | 7.1 |
| Kim et al.9 | Bladder cancer (MSKCC) | 109 | 23.0 | 2.8 | 12.0 | 13.0 | 5.0 | 32.8 | Y | 44.2 | 11.0 | 12.0 | 32.8 |
| Guo et al.10 | Bladder urothelial carcinoma (BGI) | 99 | 24.0 | 2.0 | 10.0 | 6.0 | 2.0 | 20.0 | Y | 56.0 | 6.1 | 17.9 | 20.0 |
| Weinstein et al.11 | Bladder urothelial carcinoma (TCGA) | 130 | 20.0 | 1.5 | 9.0 | 11.0 | 4.0 | 25.5 | Y | 54.5 | 9.2 | 10.8 | 25.5 |
| Al-Ahmadie et al.12 | Bladder cancer, plasmacytoid variant (MSKCC) | 31 | 16.0 | 6.0 | 16.0 | 16.0 | 3.0 | 41.0 | Y | 43.0 | 3.2 | 12.8 | 41.0 |
| Van Allen et al.13 | Bladder urothelial carcinoma (Dana Farber and MSKCC) | 50 | 20.0 | 6.0 | 8.0 | 24.0 | 34.0 | 72.0 | Y | 8.0 | 14.0 | 6.0 | 72.0 |
| Johnson et al.14 | Low grade gliomas (USCF) | 23 | 9.0 | 0.0 | 9.0 | 9.0 | 13.0 | 31.0 | Y | 60.0 | 4.3 | 4.7 | 31.0 |
| Ceccarelli et al.15 | Merged cohort of LGG and GBM (TCGA) | 812 | 8.0 | 11.0 | 0.2 | 0.0 | 0.4 | 11.6 | Y | 80.4 | 1.1 | 6.9 | 11.6 |
| Lee et al.16 | Malignant peripheral nerve sheath tumor (MSKCC) | 15 | 7.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | N | 93.0 | 0.0 | 7.0 | 0.0 |
| Ho et al.17 | Adenoid cystic carcinoma (MSKCC) | 60 | 5.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | N | 95.0 | 0.0 | 5.0 | 0.0 |
| Mitani et al.18 | Adenoid cystic carcinoma (MDA) | 102 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | N | 100.0 | 0.0 | 0.0 | 0.0 |
| Ross et al.19 | Adenoid cystic Carcinoma (FMI) | 15 | 7.0 | 7.0 | 0.0 | 0.0 | 0.0 | 7.0 | N | 86.0 | 0.0 | 7.0 | 7.0 |
| Shah et al.20 | Breast invasive carcinoma (British Columbia) | 65 | 11.0 | 1.5 | 3.0 | 0.0 | 1.5 | 6.0 | Y | 83.0 | 1.5 | 9.5 | 6.0 |
| Banerji et al.21 | Breast invasive carcinoma (Broad) | 103 | 27.0 | 2.9 | 2.9 | 1.0 | 1.0 | 7.8 | N | 65.2 | 0.0 | 27.0 | 7.8 |
| Stephens et al.22 | Breast invasive carcinoma (Sanger) | 100 | 30.0 | 0.0 | 1.0 | 3.0 | 4.0 | 8.0 | y | 62.0 | 3.0 | 27.0 | 8.0 |
| Ciriello et al.23 | Breast invasive carcinoma (TCGA) | 817 | 35.0 | 0.6 | 2.2 | 2.2 | 1.3 | 6.3 | Y | 58.7 | 2.7 | 32.3 | 6.3 |
| Pereira et al.24 | Breast cancer (METABRIC) | 1904 | 42.0 | 1.4 | 3.0 | 2.6 | 1.4 | 8.4 | Y | 49.6 | 2.9 | 39.1 | 8.4 |
| TCGA | Cervical squamous cell carcinoma and endocervical adenocarcinoma (TCGA, provisional) | 194 | 27.0 | 2.1 | 5.0 | 6.0 | 2.1 | 15.2 | Y | 57.8 | 6.2 | 20.8 | 15.2 |
| Seshagiri et al.25 | Colorectal adenocarcinoma (Genentech) | 72 | 31.0 | 6.0 | 2.8 | 8.0 | 11.0 | 27.8 | Y | 41.2 | 11.1 | 19.9 | 27.8 |
| Muzny et al.26 | Colorectal adenocarcinoma (TCGA) | 224 | 20.0 | 4.0 | 4.0 | 6.0 | 8.0 | 22.0 | Y | 58.0 | 4.9 | 15.1 | 22.0 |
| Giannakis et al.27 | Colorectal adenocarcinoma (DFCI) | 619 | 21.0 | 4.0 | 6.0 | 6.0 | 5.0 | 21.0 | Y | 58.0 | 6.1 | 14.9 | 21.0 |
| Brannon et al.28 | Colorectal adendocarcinoma triplets (MSKCC) | 69 | 22.0 | 1.4 | 4.0 | 6.0 | 4.0 | 15.4 | N | 62.6 | 0.0 | 22.0 | 15.4 |
| TCGA | Esophageal carcinoma (TCGA, provisional) | 185 | 10.0 | 2.7 | 6.0 | 3.0 | 9.0 | 20.7 | Y | 69.3 | 1.6 | 8.4 | 20.7 |
| Dulak et al.29 | Esophageal adenocarcinoma (Broad) | 146 | 5.0 | 2.1 | 3.0 | 3.0 | 10.0 | 18.1 | N | 76.9 | 0.0 | 5.0 | 18.1 |
| Song et al.30 | Esophageal squamous cell carcinoma (ICGC) | 88 | 5.0 | 0.0 | 0.0 | 1.1 | 0.0 | 1.1 | N | 93.9 | 0.0 | 5.0 | 1.1 |
| Lin et al.31 | Esophageal squamous cell carcinoma (UCLA) | 137 | 8.0 | 0.7 | 0.0 | 0.0 | 4.0 | 4.7 | N | 87.3 | 0.0 | 8.0 | 4.7 |
| Stransky et al.32 | Head and neck squamous cell Carcinoma (Broad) | 74 | 8.0 | 2.7 | 2.7 | 1.4 | 1.4 | 8.2 | Y | 83.8 | 1.4 | 6.6 | 8.2 |
| Agrawal et al.33 | Head and neck squamous cell carcinoma (Johns Hopkins) | 32 | 9.0 | 0.0 | 3.0 | 0.0 | 3.0 | 6.0 | N | 85.0 | 0.0 | 9.0 | 6.0 |
| Lawrence et al.34 | Head and neck squamous cell carcinoma (TCGA) | 279 | 21.0 | 5.0 | 1.8 | 2.9 | 5.0 | 14.7 | Y | 64.3 | 3.9 | 17.1 | 14.7 |
| Pickering et al.35 | Oral squamous cell carcinoma (MD Anderson) | 40 | 15.0 | 5.0 | 0.0 | 0.0 | 2.5 | 7.5 | N | 77.5 | 0.0 | 15.0 | 7.5 |
| Luc et al.36 | Recurrent and metastatic head and neck cancer (MSKCC?) | 132 | 14.0 | 3.0 | 0.8 | 3.0 | 7.0 | 13.8 | Y | 72.2 | 4.5 | 9.5 | 13.8 |
| Lin et al.37 | Nasopharyngeal carcinoma (Singapore) | 56 | 1.8 | 0.0 | 1.8 | 4.0 | 0.0 | 5.8 | N | 92.4 | 0.0 | 1.8 | 5.8 |
| Davis et al.38 | Kidney chromophobe (TCGA) | 65 | 0.0 | 0.0 | 0.0 | 1.5 | 1.5 | 3.0 | N | 97.0 | 0.0 | 0.0 | 3.0 |
| TCGA | Kidney renal papillary cell carcinoma (TCGA, provisional) | 282 | 1.8 | 0.4 | 1.1 | 0.7 | 1.4 | 3.6 | N | 94.6 | 0.0 | 1.8 | 3.6 |
| Guo et al.39 | Kidney renal clear cell carcinoma (BGI) | 98 | 1.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | N | 99.0 | 0.0 | 1.0 | 0.0 |
| Creighton et al.40 | Kidney renal clear cell carcinoma (TCGA) | 424 | 2.6 | 1.7 | 0.9 | 0.7 | 1.4 | 4.7 | N | 92.7 | 0.0 | 2.6 | 4.7 |
| Sato et al.41 | Clear cell renal cell carcinoma (U Tokyo) | 106 | 5.0 | 0.9 | 0.0 | 0.9 | 0.9 | 2.7 | Y | 92.3 | 0.9 | 4.1 | 2.7 |
| Gerlinger et al.42 | Multiregion sequencing of clear cell renal cell carcinoma (IRC) | 10 | 20.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | N | 80.0 | 0.0 | 20.0 | 0.0 |
| Durinck et al.43 | Renal non-clear cell carcinoma (Genentech) | 138 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | N | 100.0 | 0.0 | 0.0 | 0.0 |
| Ahn et al.44 | Liver hepatocellular carcinoma (AMC) | 231 | 0.9 | 0.9 | 1.3 | 2.2 | 3.0 | 7.4 | N | 91.7 | 0.0 | 0.9 | 7.4 |
| Fujimoto et al.45 | Liver hepatocellular carcinoma (RIKEN) | 21 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | N | 100.0 | 0.0 | 0.0 | 0.0 |
| TCGA | Liver hepatocellular carcinoma (TCGA provisional) | 373 | 3.0 | 1.6 | 1.1 | 2.1 | 2.9 | 7.7 | Y | 89.3 | 0.5 | 2.5 | 7.7 |
| Jiao et al.46 | Intrahepatic cholangiocarcinoma (Johns Hopkins University) | 40 | 8.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | N | 92.0 | 0.0 | 8.0 | 0.0 |
| Chan-On et al.47 | Cholangiocarcinoma (National Cancer Centre of Singapore) | 15 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | N | 100.0 | 0.0 | 0.0 | 0.0 |
| TCGA | Cholangiocarcinoma (TCGA, provisional) | 35 | 6.0 | 2.9 | 6.0 | 0.0 | 9.0 | 17.9 | N | 76.1 | 0.0 | 6.0 | 17.9 |
| Li et al.48 | Gallbladder carcinoma (Shanghai) | 32 | 6.0 | 3.0 | 9.0 | 9.0 | 0.0 | 21.0 | Y | 73.0 | 3.1 | 2.9 | 21.0 |
| Imielinksi et al.49 | Lung adenocarcinoma (Broad) | 183 | 4.0 | 17.0 | 2.2 | 2.7 | 8.0 | 29.9 | Y | 66.1 | 1.1 | 2.9 | 29.9 |
| Campbell et al.50 | Pan-lung cancer (TCGA) | 1144 | 8.0 | 10.0 | 2.3 | 2.4 | 9.0 | 23.7 | Y | 68.3 | 1.5 | 6.5 | 23.7 |
| Ding et al.51 | Lung adenocarcinoma (TSP) | 163 | 0.6 | 18.0 | 1.8 | 1.8 | 5.0 | 26.6 | N | 72.8 | 0.0 | 0.6 | 26.6 |
| MSKCC | Lung adenocarcinoma (MSKCC) | 34 | 2.9 | 6.0 | 0.0 | 6.0 | 6.0 | 18.0 | N | 79.1 | 0.0 | 2.9 | 18.0 |
| Peifer et al.52 | Small cell lung cancer (CLCGP) | 29 | 0.0 | 3.0 | 3.0 | 0.0 | 21.0 | 27.0 | N | 73.0 | 0.0 | 0.0 | 27.0 |
| Rudin et al.53 | Small cell lung cancer (Johns Hopkins) | 42 | 5.0 | 0.0 | 0.0 | 0.0 | 5.0 | 5.0 | N | 90.0 | 0.0 | 5.0 | 5.0 |
| Geroge et al.54 | Small cell lung cancer (U Cologne) | 110 | 2.7 | 4.0 | 0.9 | 0.9 | 9.0 | 14.8 | N | 82.5 | 0.0 | 2.7 | 14.8 |
| Bell et al.55 | Ovarian serous cystadenocarcinoma (TCGA) | 316 | 0.6 | 1.9 | 0.9 | 0.6 | 0.0 | 3.4 | N | 96.0 | 0.0 | 0.6 | 3.4 |
| Biankin et al.56 | Pancreatic adenocarcinoma (ICGC) | 99 | 0.0 | 0.0 | 0.0 | 0.0 | 1.0 | 1.0 | N | 99.0 | 0.0 | 0.0 | 1.0 |
| TCGA | Pancreatic carcinoma (TCGA, provisional) | 150 | 2.7 | 0.7 | 1.3 | 2.0 | 1.3 | 5.3 | N | 92.0 | 0.0 | 2.7 | 5.3 |
| Bailey et al.57 | Pancreatic adenocarcinoma (QCMG) | 383 | 1.6 | 0.0 | 0.5 | 0.5 | 1.0 | 2.0 | N | 96.4 | 0.0 | 1.6 | 2.0 |
| Witkiewicz et al.58 | Pancreatic cancer (UTSW) | 109 | 4.0 | 0.9 | 0.9 | 0.0 | 2.8 | 4.6 | N | 91.4 | 0.0 | 4.0 | 4.6 |
| Jiao et al.59 | Acinar cell carcinoma of the pancreas (John Hopkins) | 23 | 0.0 | 0.0 | 0.0 | 4.0 | 0.0 | 4.0 | N | 96.0 | 0.0 | 0.0 | 4.0 |
| Robinson et al.60 | Metastatic prostate cancer (SU2C/PCF Dream team) | 150 | 5.0 | 0.7 | 0.7 | 0.7 | 1.3 | 3.4 | Y | 91.6 | 0.7 | 4.3 | 3.4 |
| Grasso et al.61 | Prostate adenocarcinoma, metastatic (Michigan) | 59 | 0.0 | 0.0 | 1.7 | 0.0 | 0.0 | 1.7 | N | 98.3 | 0.0 | 0.0 | 1.7 |
| Trento/Cornell/Broad 2016 | Neuroendocrine prostate cancer (Trento/Cornell/Broad 2016) | 81 | 1.2 | 0.0 | 2.5 | 1.2 | 0.0 | 3.7 | N | 95.1 | 1.2 | 0.0 | 3.7 |
| Kumar et al.62 | Prostate adenocarcinoma (Fred Hutchinson CRC) | 56 | 4.0 | 4.0 | 1.8 | 4.0 | 0.0 | 9.8 | Y | 86.2 | 1.8 | 2.2 | 9.8 |
| Barbieri et al.63 | Prostate adenocarcinoma (Broad/Cornell) | 112 | 4.0 | 0.9 | 0.9 | 0.0 | 0.0 | 1.8 | N | 94.2 | 0.0 | 4.0 | 1.8 |
| Taylor et al.64 | Prostate adenocarcinoma (MSKCC) | 103 | 2.9 | 1.9 | 1.9 | 1.0 | 0.0 | 4.8 | N | 92.3 | 0.0 | 2.9 | 4.8 |
| Abeshouse et al.65 | Prostate adenocarcinoma (TCGA) | 333 | 1.8 | 1.2 | 0.0 | 0.6 | 0.6 | 2.4 | Y | 95.8 | 0.3 | 1.5 | 2.4 |
| Wang et al.66 | Stomach adenocarcinoma (Pfizer and UHK) | 100 | 2.0 | 4.0 | 7.0 | 5.0 | 3.0 | 19.0 | Y | 79.0 | 2.0 | 0.0 | 19.0 |
| Bass et al.67 | Stomach adenocarcinoma (TCGA) | 289 | 20.0 | 5.0 | 5.0 | 11.0 | 13.0 | 34.0 | Y | 46.0 | 8.3 | 11.7 | 34.0 |
| Kakiuchi et al.68 | Stomach adenocarcinoma (U Tokyo) | 30 | 3.0 | 3.0 | 3.0 | 0.0 | 0.0 | 6.0 | N | 91.0 | 0.0 | 3.0 | 6.0 |
| Chen et al.69 | Gastric adenocarcinoma (TMUCIH) | 78 | 13.0 | 1.3 | 4.0 | 2.6 | 9.0 | 16.9 | Y | 70.1 | 1.3 | 11.7 | 16.9 |
| Agrawal et al.70 | Papillary thyroid carcinoma (TCGA) | 401 | 0.5 | 0.0 | 0.2 | 0.2 | 0.5 | 0.9 | N | 98.6 | 0.0 | 0.5 | 0.9 |
| Landa et al.71 | Poorly differentiated and anaplastic thyroid cancers (MSKCC) | 117 | 7.0 | 0.9 | 1.7 | 0.0 | 0.0 | 2.6 | N | 90.4 | 0.0 | 7.0 | 2.6 |
| Hodis et al.72 | Skin cutaneous melanoma (Broad) | 121 | 5.0 | 6.0 | 1.7 | 6.0 | 16.0 | 29.7 | Y | 65.3 | 0.8 | 4.2 | 29.7 |
| TCGA | Skin cutaneous melanoma (TCGA, provisional) | 366 | 3.0 | 7.0 | 2.5 | 2.2 | 16.0 | 27.7 | Y | 69.3 | 1.6 | 1.4 | 27.7 |
| Li et al.73 | Cutaneous squamous cell carcinoma (DFCI) | 29 | 14.0 | 14.0 | 17.0 | 14.0 | 31.0 | 76.0 | Y | 10.0 | 10.3 | 3.7 | 76.0 |
| Shain et al.74 | Desmoplastic melanoma (Broad ) | 20 | 5.0 | 5.0 | 0.0 | 5.0 | 30.0 | 40.0 | Y | 55.0 | 5.0 | 0.0 | 40.0 |
| Krauthammer et al.75 | Skin cutaneous melanoma (Yale) | 91 | 0.0 | 4.0 | 1.1 | 2.2 | 11.0 | 18.3 | N | 81.7 | 0.0 | 0.0 | 18.3 |
| TCGA | Testicular germ cell cancer (TCGA provisional) | 149 | 2.0 | 0.7 | 2.0 | 1.3 | 0.0 | 4.0 | N | 94.0 | 0.0 | 2.0 | 4.0 |
| TCGA | Uterine carcinosarcoma (TCGA, provisional) | 57 | 35.0 | 0.0 | 1.8 | 7.0 | 0.0 | 8.8 | Y | 56.2 | 3.5 | 31.5 | 8.8 |
| Jones et al.76 | Uterine carcinosarcoma (Johns Hopkins University) | 22 | 41.0 | 9.0 | 9.0 | 14.0 | 5.0 | 37.0 | Y | 22.0 | 22.7 | 18.3 | 37.0 |
| Kandoth et al.77 | Uterine corpus endometrioid carcinoma (TCGA) | 248 | 53.0 | 3.0 | 3.0 | 7.0 | 6.0 | 19.0 | Y | 28.0 | 11.3 | 41.7 | 19.0 |
Mut, mutation; WT, wild type.